[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,73,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100553470","proximal-femur-reconstruction-following-resection-of-primary-bone-tumors-analysis-of-the-clinical-and-radiographic-results-100553470",false,"NCT06486506","Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic Results","ProFemuRe","Inclusion Criteria:\n\n* Male and female patients surgically treated with an oncological reconstruction of the proximal femur at Rizzoli Orthopaedic Institute between 01\u002F01\u002F1991 and 31\u002F12\u002F2023\n* Age: 18-90 years old (at the time of primary surgery)\n* Diagnosis of bone sarcoma\n* Patients with available clinical and imaging data\n\nExclusion Criteria:\n\n* At least one inclusion criterion not met","ALL","18 Years","90 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","From the archives of the Rizzoli institute all the patients (approximately 150 patients) undergoing oncological reconstruction of proximal femur from 01\u002F01\u002F1991 to 31\u002F12\u002F2023.\n\nA review will be made from the medical records, radiological imaging, and histological data of these patients",[25,26],"Bone Tumor","Bone Cancer",[28,29,30],"Proximal Femur Reconstruction","primary bone tumors","imaging","RECRUITING","2026-05-21",{"date":34,"type":35},"2026-05-26","ACTUAL",{"date":37,"type":35},"2024-04-29",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Costantino Errani","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100636032","phase-1-treatment-of-truncated-alk-positive-bone-cancer-using-crizotinib-xalkori-or-alectinib-alecensa-100636032","NCT07560410","Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)","Inclusion Criteria:\n\n* Age ≥ 20 years.\n* Patients with locally advanced or metastatic solid tumors harboring deficiency or alteration of anaplastic lymphoma kinase (ALK) tyrosine kinase.\n* Disease progression during or within 6 months after completion of standard therapy, or no appropriate standard treatment available.\n* At least one measurable lesion according to applicable response evaluation criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Estimated life expectancy of at least 8 weeks.\n\nExclusion Criteria:\n\n* Known hypersensitivity to crizotinib or alectinib.\n* Current or prior use of ALK inhibitors.\n* Current use of tyrosine kinase inhibitors.\n* Receipt of radiotherapy within 2 weeks prior to study entry. Palliative radiotherapy to non-target lesions is permitted.\n* History of other malignancies, except for osteosarcoma or chondrosarcoma, unless the patient has been disease-free for at least 2 years. Exceptions include adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Liver cirrhosis with a Child-Pugh score ≥ 8.\n* Uncorrectable electrolyte abnormalities.\n* Presence of brain metastases.\n* Active acute infection.\n* Significant unresolved toxicity from prior therapy.\n* Comorbid conditions that may interfere with study participation, including but not limited to uncontrolled diabetes mellitus, autoimmune diseases, or any condition that, in the investigator's judgment, renders the patient unsuitable for the study.\n* Concurrent malignancy, unless it is adequately treated carcinoma in situ or basal cell carcinoma, or a malignancy that has been treated and has remained recurrence-free for at least 3 years.\n* Pregnant or breastfeeding women.\n* Patients with psychiatric disorders that may impair compliance with study requirements.\n* Current use of strong inducers or inhibitors of CYP3A enzymes, or use of other investigational or non-approved drugs.","20 Years","80 Years",{"count":53,"type":21},10,"INTERVENTIONAL",[56,57],"PHASE1","PHASE2","This is an investigator-initiated, single-center clinical trial evaluating the efficacy and safety of ALK inhibitors in patients with locally advanced or metastatic bone cancer harboring truncated ALK (ALKATI) alterations. Eligible patients must have disease progression after standard therapy or no suitable standard treatment options.\n\nParticipants will receive either crizotinib (Xalkori®) or alectinib (Alecensa®), with treatment selection determined by the study investigators. The study aims to assess antitumor activity, safety, and clinical outcomes in this rare molecular subtype of bone cancer.",[26],[61,62],"bone cancer","Truncated ALK (ALKATI)","NOT_YET_RECRUITING","2026-05-05",{"date":66,"type":35},"2026-05-11",{"date":68,"type":21},"2026-05-15",{"date":70,"type":21},"2029-04-14",{"name":72,"class":42},"China Medical University Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":43},"100298073","genetic-analysis-of-pheochromocytomas-paragangliomas-and-associated-conditions-100298073","NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Inclusion Criteria:\n\n* diagnosis of pheochromocytoma and or paraganglioma\n* family member with diagnosis of pheochromocytoma and or paraganglioma\n* diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n* family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of pheochromocytoma and\u002For paraganglioma or associated condition",true,{"count":81,"type":21},2000,"30 Years","Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma\u002Fparaganglioma of various genetic origins.",[85,86,87,88,89,26,90,91],"Pheochromocytoma","Paraganglioma","Inherited Cancer Syndrome","Associated Conditions","Kidney Neoplasms","Thyroid Neoplasms","Other Cancer",[93,94,95,96],"tumor suppressor gene","oncogene","mutation","susceptibility gene","2025-10-13",{"date":99,"type":35},"2025-10-15",{"date":101,"type":35},"2005-10-19",{"date":103,"type":21},"2030-12-31",{"name":105,"class":42},"The University of Texas Health Science Center at San Antonio",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100521489","insights-into-participating-in-studies-for-bone-cancer-100521489","NCT06070259","Insights Into Participating in Studies for Bone Cancer","Examining Patient Involvement Patterns and Trends in Participation in Bone Cancer Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Diagnosis of bone cancer\n* No prior treatment for bone cancer\n\nExclusion Criteria:\n\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Enrolled in another research study\n* Inability to provide written informed consent",{"count":114,"type":21},500,"Clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption.\n\nThe primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.",[26],[26],"2023-09-30",{"date":120,"type":35},"2023-10-06",{"date":122,"type":21},"2024-10",{"date":124,"type":21},"2026-10",{"name":126,"class":127},"Power Life Sciences Inc.","INDUSTRY"]